Lexicon Pharmaceuticals (LXRX) Posts Q3 Loss of 6c/Share
Tweet
Share
E-mailGet Alerts LXRX Hot Sheet
Price: $2.17 +0.93%
EPS Growth %: -600.0%
Financial Fact:
Subscription and license fees: 31K
Today's EPS Names:
MAYS, CRMT, REPL, More
EPS Growth %: -600.0%
Financial Fact:
Subscription and license fees: 31K
Today's EPS Names:
MAYS, CRMT, REPL, More
Join SI Premium – FREE
Lexicon Pharmaceuticals (NASDAQ: LXRX) reported Q3 EPS of ($0.06), in-line with the analyst estimate of ($0.06). Revenue for the quarter came in at $372 thousand versus the consensus estimate of $600 thousand.
For earnings history and earnings-related data on Lexicon Pharmaceuticals (LXRX) click here.
For earnings history and earnings-related data on Lexicon Pharmaceuticals (LXRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
- Morgan Stanley upgrades CDW on stronger AI-driven server demand
- B.C. households cutting back on groceries and essentials as cost-of-living crisis worsens: new survey
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
